BAFNA PHARMACEUTICALS Financial Statement Analysis
|
||
|
The Revenues of BAFNA PHARMACEUTICALS have increased by 32.18% YoY .
The Earnings Per Share (EPS) of BAFNA PHARMACEUTICALS has decreased by -43.41 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
BAFNA PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 532989|NSE : BAFNAPH]
| Standalone | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹152 Cr | ₹115 Cr | ₹85 Cr | ₹71 Cr | ₹42 Cr |
| Expenses | ₹141 Cr | ₹100 Cr | ₹73 Cr | ₹61 Cr | ₹41 Cr |
| Operating Profit (Excl OI) | ₹11 Cr | ₹16 Cr | ₹12 Cr | ₹10 Cr | ₹1.23 Cr |
| Other Income | ₹3.52 Cr | ₹3.27 Cr | ₹1.76 Cr | ₹0.75 Cr | ₹0.26 Cr |
| Interest | ₹2.29 Cr | ₹2.04 Cr | ₹0.79 Cr | ₹0.74 Cr | ₹0.10 Cr |
| Depreciation | ₹5.00 Cr | ₹5.33 Cr | ₹5.49 Cr | ₹4.48 Cr | ₹3.27 Cr |
| Profit Before Tax | ₹7.35 Cr | ₹12 Cr | ₹5.22 Cr | ₹5.83 Cr | ₹-1.88 Cr |
| Profit After Tax | ₹7.35 Cr | ₹11 Cr | ₹5.22 Cr | ₹5.83 Cr | ₹-1.88 Cr |
| Earnings Per Share (Rs) | ₹1.76 | ₹3.11 | ₹4.79 | ₹2.21 | ₹2.46 |
| PAT Margin (%) | 2.85 | 4.82 | 9.83 | 6.13 | 8.18 |
| ROE(%) | 5.01 | 9.52 | 16.75 | 8.79 | 22.26 |
| ROCE(%) | 6.31 | 9.56 | 16.12 | 8.42 | 10.62 |
| Total Debt/Equity(x) | 0.33 | 0.30 | 0.31 | 0.18 | 0.23 |
Key Financials |
||
| Market Cap | : | ₹ 354.7 Cr |
| Revenue (TTM) | : | ₹ 142.3 Cr |
| Net Profit(TTM) | : | ₹ 8.8 Cr |
| EPS (TTM) | : | ₹ 3.7 |
| P/E (TTM) | : | 40.4 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| BAFNA PHARMACEUTICALS | 0.4% | -15.9% | 72.1% |
| SUN PHARMACEUTICAL INDUSTRIES | -2.9% | -1.8% | -2.5% |
| DIVIS LABORATORIES | 2.1% | 0.2% | 9.1% |
| CIPLA | 0.7% | -0.8% | 3.4% |
| TORRENT PHARMACEUTICALS | 0.5% | 2.2% | 11.2% |
| DR REDDYS LABORATORIES | -0.1% | 2.5% | 2.5% |
| MANKIND PHARMA | 1.5% | -2.8% | -19.5% |
| ZYDUS LIFESCIENCES | -0.2% | -0.8% | -5.7% |
| LUPIN | 1.7% | 4.7% | 3.5% |
BAFNA PHARMACEUTICALS Revenues
[BOM: 532989|NSE : BAFNAPH]
| Y-o-Y | 32.18 % |
| 5 Yr CAGR | 37.65 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹152 Cr | 32.18 | |
| Mar2024 | ₹115 Cr | 35.48 | |
| Mar2023 | ₹85 Cr | 19.55 | |
| Mar2022 | ₹71 Cr | 67.68 | |
| Mar2021 | ₹42 Cr | - | |
BAFNA PHARMACEUTICALS Operating Profit
[BOM: 532989|NSE : BAFNAPH]
| Y-o-Y | -29.30 % |
| 5 Yr CAGR | 73.40 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹11 Cr | -29.30 | |
| Mar2024 | ₹16 Cr | 32.02 | |
| Mar2023 | ₹12 Cr | 15.60 | |
| Mar2022 | ₹10 Cr | 737.92 | |
| Mar2021 | ₹1.23 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -46.48 % |
| 5 Yr CAGR | 26.03 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 7.29% | -46.48 | |
| Mar2024 | 13.62% | -2.58 | |
| Mar2023 | 13.98% | -3.32 | |
| Mar2022 | 14.46% | 400.35 | |
| Mar2021 | 2.89% | - | |
BAFNA PHARMACEUTICALS Profit After Tax
[BOM: 532989|NSE : BAFNAPH]
| Y-o-Y | -35.19 % |
| 5 Yr CAGR | Positive |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹7.35 Cr | -35.19 | |
| Mar2024 | ₹11 Cr | 117.33 | |
| Mar2023 | ₹5.22 Cr | -10.47 | |
| Mar2022 | ₹5.83 Cr | Positive | |
| Mar2021 | ₹-1.88 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -40.87 % |
| 5 Yr CAGR | -23.17 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 2.85 % | -40.87 | |
| Mar2024 | 4.82 % | -50.97 | |
| Mar2023 | 9.83 % | 60.36 | |
| Mar2022 | 6.13 % | -25.06 | |
| Mar2021 | 8.18 % | - | |
BAFNA PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 532989|NSE : BAFNAPH]
| Y-o-Y | -43.41 % |
| 5 Yr CAGR | -8.03 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹1.76 | -43.41 | |
| Mar2024 | ₹3.11 | -35.07 | |
| Mar2023 | ₹4.79 | 116.74 | |
| Mar2022 | ₹2.21 | -10.16 | |
| Mar2021 | ₹2.46 | - | |
BAFNA PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 532989|NSE : BAFNAPH]
| Y-o-Y | -34.00 % |
| 5 Yr CAGR | -12.20 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 6.31% | -34.00 | |
| Mar2024 | 9.56% | -40.69 | |
| Mar2023 | 16.12% | 91.45 | |
| Mar2022 | 8.42% | -20.72 | |
| Mar2021 | 10.62% | - | |
BAFNA PHARMACEUTICALS Share Price vs Sensex
| Current Share Price | : | ₹149.7 |
| Current MarketCap | : | ₹ 354.7 Cr |
| Updated EOD on | : | Dec 19,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| BAFNA PHARMACEUTICALS | 0.4% |
-15.9% |
72.1% |
| SENSEX | -0.4% |
-0.3% |
3.9% |
BAFNA PHARMACEUTICALS related INDICES
No BSE index found!
No NSE index found
You may also like the below Video Courses
FAQ about BAFNA PHARMACEUTICALS Financials
How the annual revenues of BAFNA PHARMACEUTICALS have changed ?
The Revenues of BAFNA PHARMACEUTICALS have increased by 32.18% YoY .
How the Earnings per Share (EPS) of BAFNA PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of BAFNA PHARMACEUTICALS has decreased by -43.41 % YoY .
Check out Intrinsic Value of Peers of BAFNA PHARMACEUTICALS
Compare Stock Analytics of Peers of BAFNA PHARMACEUTICALS
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
